Virax Biolabs Group (VRAX) FDA Approvals $3.12 -0.07 (-2.04%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings Virax Biolabs Group's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Virax Biolabs Group (VRAX). Over the past two years, Virax Biolabs Group has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ViraxImmune. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ViraxImmune FDA Regulatory Events ViraxImmune is a drug developed by Virax Biolabs Group for the following indication: Long COVID and Related Post-Acute Infection Syndromes. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement Virax Biolabs Group FDA Events - Frequently Asked Questions Has Virax Biolabs Group received FDA approval? As of now, Virax Biolabs Group (VRAX) has not received any FDA approvals for its therapy in the last two years. What drugs has Virax Biolabs Group submitted to the FDA? In the past two years, Virax Biolabs Group (VRAX) has reported FDA regulatory activity for ViraxImmune. What is the most recent FDA event for Virax Biolabs Group? The most recent FDA-related event for Virax Biolabs Group occurred on May 26, 2026, involving ViraxImmune. The update was categorized as "Positive Data," with the company reporting: "Virax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS")." What conditions do Virax Biolabs Group's current drugs treat? Currently, Virax Biolabs Group has one therapy (ViraxImmune) targeting the following condition: Long COVID and Related Post-Acute Infection Syndromes. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsBriacell Therap FDA EventsBiomea Fusion FDA EventsCapricor Therapeutics FDA EventsPrecision BioSciences FDA EventsErasca FDA EventsGilead Sciences FDA EventsMonte Rosa Therapeutics FDA EventsInsmed FDA EventsLiminatus Pharma FDA EventsPTC Therapeutics FDA EventsREGENXBIO FDA EventsRhythm Pharmaceuticals FDA EventsTiziana Life Sciences FDA EventsUnited Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies ENDRA Life Sciences FDA Events Beyond Air FDA Events PAVmed FDA Events Aethlon Medical FDA Events Bluejay Diagnostics FDA Events Strata Skin Sciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:VRAX last updated on 5/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe government values gold at $42. It's really $4,800.The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredAmerica’s new money explainedThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement
